Table 1 Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 177 all breast cancers
Parameters | PD-1 | p value | PD-L1 | p value | PD-L2 | p value | |||
|---|---|---|---|---|---|---|---|---|---|
Positive (n = 37) | Negative (n = 140) | Positive (n = 42) | Negative (n = 135) | Positive (n = 53) | Negative (n = 124) | ||||
Intrinsic subtype | |||||||||
TNBC | 18 (48.6%) | 43 (30.7%) | 0.041 | 24 (57.1%) | 37 (27.4%) | < 0.001 | 20 (37.7%) | 41 (33.1%) | 0.549 |
Non-TNBC | 19 (51.4%) | 97 (69.3%) | 18 (42.9%) | 98 (72.6%) | 33 (62.3%) | 83 (66.9%) | |||
Intrinsic subtype | |||||||||
HER2+BC | 3 (81.1%) | 42 (30.0%) | 0.004 | 4 (9.5%) | 41 (30.4%) | 0.004 | 16 (30.2%) | 29 (23.4%) | 0.341 |
Non-HER2+ BC | 34 (18.9%) | 98 (70.0%) | 38 (90.5%) | 94 (69.6%) | 37 (69.8%) | 95 (76.6%) | |||
Age at operation | |||||||||
≤ 56 | 15 (40.5%) | 72 (51.4%) | 0.239 | 20 (47.6%) | 67 (49.6%) | 0.820 | 28 (52.8%) | 59 (47.6%) | 0.522 |
> 56 | 22 (59.5%) | 68 (48.6%) | 22 (52.4%) | 68 (50.4%) | 25 (47.2%) | 65 (52.4%) | |||
Menopause | |||||||||
Negative | 14 (37.8%) | 58 (41.4%) | 0.693 | 18 (42.9%) | 54 (40.0%) | 0.742 | 23 (43.4%) | 49 (39.5%) | 0.630 |
Positive | 23 (62.2%) | 82 (58.6%) | 24 (57.1%) | 81 (60.0%) | 30 (56.6%) | 75 (60.5%) | |||
Tumor size (cm) | |||||||||
≤ 2 | 5 (13.5%) | 19 (13.6%) | 0.993 | 6 (14.3%) | 18 (13.3%) | 0.875 | 9 (17.0%) | 15 (12.1%) | 0.385 |
> 2 | 32 (86.5%) | 121 (86.4%) | 36 (85.7%) | 117 (86.7%) | 44 (83.0%) | 109 (87.9%) | |||
Lymph node status | |||||||||
Negative | 7 (18.9%) | 34 (24.3%) | 0.491 | 10 (23.8%) | 31 (23.0%) | 0.910 | 12 (22.6%) | 29 (23.4%) | 0.914 |
Positive | 30 (81.1%) | 106 (75.7%) | 32 (76.2%) | 104 (77.0%) | 41 (77.4%) | 95 (76.6%) | |||
Nuclear grade | |||||||||
1, 2 | 26 (70.3%) | 111 (79.3%) | 0.244 | 31 (73.8%) | 106 (78.5%) | 0.524 | 39 (73.6%) | 98 (79.0%) | 0.427 |
3 | 11 (29.7%) | 29 (20.7%) | 11 (26.2%) | 29 (21.5%) | 14 (26.4%) | 26 (21.0%) | |||
Ki67 | |||||||||
≤ 14% | 13 (35.1%) | 61 (43.6%) | 0.355 | 16 (38.1%) | 58 (43.0%) | 0.576 | 18 (34.0%) | 56 (45.2%) | 0.167 |
> 14% | 24 (64.9%) | 79 (56.4%) | 26 (61.9%) | 77 (57.0%) | 35 (66.0%) | 68 (54.8%) | |||
Pathological response | |||||||||
pCR | 9 (24.3%) | 58 (41.4%) | 0.056 | 6 (14.3%) | 61 (45.2%) | < 0.001 | 24 (45.3%) | 43 (34.7%) | 0.183 |
Non-pCR | 28 (75.7%) | 82 (58.6%) | 36 (85.7%) | 74 (54.8%) | 29 (54.7%) | 81 (65.3%) | |||
PD-1 | |||||||||
Negative | Not determined | Not determined | 13 (31.0%) | 127 (94.1%) | < 0.001 | 31 (58.5%) | 109 (87.9%) | < 0.001 | |
Positive | 29 (69.0%) | 8 (5.9%) | 22 (41.5%) | 15 (12.1%) | |||||
PD-L1 | |||||||||
Negative | 8 (21.6%) | 127 (90.7%) | < 0.001 | Not determined | Not determined | 25 (47.2%) | 110 (88.7%) | < 0.001 | |
Positive | 29 (78.4%) | 13 (9.3%) | 28 (52.8%) | 14 (11.3%) | |||||
PD-L2 | |||||||||
Negative | 15 (40.5%) | 109 (77.9%) | < 0.001 | 14 (33.3%) | 110 (81.5%) | < 0.001 | Not determined | Not determined | |
Positive | 22 (59.5%) | 31 (22.1%) | 28 (66.7%) | 25 (18.5%) | |||||